CAM
VRTX icon

Cresset Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Cresset Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.94M Buy
7,926
+66
+0.8% +$29.3K 0.01% 477
2026
Q1 		$3.51M Buy
7,860
+305
+4% +$142K 0.02% 442
2025
Q4 		$3.43M Sell
7,555
-37
-0.5% -$15.9K 0.01% 442
2025
Q3 		$2.97M Sell
7,592
-4,635
-38% -$1.94M 0.01% 451
2025
Q2 		$5.44M Sell
12,227
-2,100
-15% -$968K 0.03% 319
2025
Q1 		$6.95M Sell
14,327
-1,691
-11% -$788K 0.03% 294
2024
Q4 		$6.45M Sell
16,018
-8,025
-33% -$3.72M 0.03% 302
2024
Q3 		$11.2M Buy
24,043
+8,004
+50% +$3.84M 0.04% 280
2024
Q2 		$7.52M Buy
16,039
+4,005
+33% +$1.74M 0.03% 345
2024
Q1 		$5.03M Buy
12,034
+961
+9% +$406K 0.02% 382
2023
Q4 		$4.51M Buy
11,073
+1,808
+20% +$668K 0.03% 366
2023
Q3 		$3.22M Sell
9,265
-1,234
-12% -$432K 0.01% 418
2023
Q2 		$3.69M Buy
10,499
+9,110
+656% +$3.07M ﹤0.01% 482
2023
Q1 		$438K Buy
+1,389
New +$417K 0.01% 520
2022
Q4 		– Sell
-1,812
Closed -$524K – 905
2022
Q3 		$524K Sell
1,812
-345
-16% -$99.3K 0.01% 497
2022
Q2 		$605K Sell
2,157
-850
-28% -$228K 0.01% 500
2022
Q1 		$785K Buy
3,007
+453
+18% +$108K 0.01% 472
2021
Q4 		$560K Sell
2,554
-465
-15% -$90.4K 0.01% 662
2021
Q3 		$548K Buy
3,019
+502
+20% +$98K 0.01% 585
2021
Q2 		$508K Buy
2,517
+152
+6% +$31.8K 0.01% 549
2021
Q1 		$508K Buy
2,365
+585
+33% +$128K 0.01% 476
2020
Q4 		$421K Sell
1,780
-317
-15% -$72.7K 0.01% 444
2020
Q3 		$570K Buy
2,097
+165
+9% +$45.5K 0.01% 351
2020
Q2 		$561K Buy
1,932
+542
+39% +$147K 0.01% 318
2020
Q1 		$331K Buy
1,390
+253
+22% +$58K 0.01% 362
2019
Q4 		$249K Buy
+1,137
New +$230K 0.01% 491
2019
Q3 		– Sell
-1,212
Closed -$222K – 564
2019
Q2 		$222K Buy
1,212
+104
+9% +$18.2K 0.01% 417
2019
Q1 		$204K Buy
1,108
+602
+119% +$111K 0.01% 370
2018
Q4 		$84K Buy
+506
New +$87.7K 0.01% 368

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Cresset Asset Management's VRTX Position: Q2 2026 in Review

Cresset Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.84% in Q2 2026, buying an estimated $29.3K and bringing the position to 7,926 shares worth $3.94M. The position accounts for 0.01% of the portfolio, ranked #477.

Cresset Asset Management first reported a position in VRTX in Q4 2018 and has held it in 29 quarters since. The position peaked at $11.2M in Q3 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Cresset Asset Management held 7,926 shares of Vertex Pharmaceuticals worth $3.94M as of Q2 2026.
  • Cresset Asset Management bought 66 Vertex Pharmaceuticals shares in Q2 2026, an estimated $29.3K.
  • Vertex Pharmaceuticals made up 0.01% of Cresset Asset Management's portfolio in Q2 2026, its #477 holding.
  • Cresset Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 29 quarters since.
  • Cresset Asset Management's Vertex Pharmaceuticals position peaked at $11.2M in Q3 2024.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.